| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GUCY1b3 |
| Uniprot No | Q02153 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-619aa |
| 氨基酸序列 | MYGFVNHALELLVIRNYGPEVWEDIKKEAQLDEEGQFLVRIIYDDSKTYDLVAAASKVLNLNAGEILQMFGKMFFVFCQESGYDTILRVLGSNVREFLQNLDALHDHLATIYPGMRAPSFRCTDAEKGKGLILHYYSEREGLQDIVIGIIKTVAQQIHGTEIDMKVIQQRNEECDHTQFLIEEKESKEEDFYEDLDRFEENGTQESRISPYTFCKAFPFHIIFDRDLVVTQCGNAIYRVLPQLQPGNCSLLSVFSLVRPHIDISFHGILSHINTVFVLRSKEGLLDVEKLECEDELTGTEISCLRLKGQMIYLPEADSILFLCSPSVMNLDDLTRRGLYLSDIPLHDATRDLVLLGEQFREEYKLTQELEILTDRLQLTLRALEDEKKKTDTLLYSVLPPSVANELRHKRPVPAKRYDNVTILFSGIVGFNAFCSKHASGEGAMKIVNLLNDLYTRFDTLTDSRKNPFVYKVETVGDKYMTVSGLPEPCIHHARSICHLALDMMEIAGQVQVDGESVQITIGIHTGEVVTGVIGQRMPRYCLFGNTVNLTSRTETTGEKGKINVSEYTYRCLMSPENSDPQFHLEHRGPVSMKGKKEPMQVWFLSRKNTGTEETKQDDD |
| 预测分子量 | 70,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GUCY1b3重组蛋白的假设性参考文献示例(仅供参考，实际文献需根据具体研究查询)：
1. **文献名称**：Structural Insights into GUCY1b3 Recombinant Protein in Nitric Oxide Signaling
**作者**：Martin F. et al. (2016)
**摘要**：解析了GUCY1b3与α亚基形成的sGC复合体晶体结构，揭示其与一氧化氮结合后的构象变化机制。
2. **文献名称**：Recombinant GUCY1b3 Expression and Functional Characterization in Cardiovascular Disease Models
**作者**：Zhang Y. et al. (2018)
**摘要**：通过大肠杆菌系统表达重组GUCY1b3蛋白，验证其在血管平滑肌细胞中调节cGMP生成的功能，并探索其与高血压的关联。
3. **文献名称**：Optimization of GUCY1b3 Recombinant Protein Production in Mammalian Cells
**作者**：Lee S. et al. (2020)
**摘要**：优化哺乳动物细胞表达体系，提高GUCY1b3重组蛋白的产量及稳定性，用于高通量药物筛选。
4. **文献名称**：Role of GUCY1b3 Mutants in sGC Dysfunction: Implications for Genetic Disorders
**作者**：Kumar R. et al. (2021)
**摘要**：通过构建GUCY1b3点突变重组蛋白，研究其酶活缺陷机制，揭示特定突变导致sGC功能异常与遗传性疾病的关联。
(注：以上为假设示例，实际文献需通过PubMed/Google Scholar等平台以“GUCY1b3 recombinant protein”“sGC expression”等关键词检索。)
GUCY1B3. also known as guanylate cyclase soluble subunit beta-1. is a critical component of the nitric oxide (NO) signaling pathway. It forms a heterodimeric complex with GUCY1A1 or GUCY1A2 (alpha subunits) to create soluble guanylate cyclase (sGC), an enzyme responsible for converting guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). This secondary messenger, cGMP, regulates diverse physiological processes, including vasodilation, platelet aggregation, and neuronal signaling. Dysregulation of the NO-sGC-cGMP pathway is implicated in cardiovascular diseases, pulmonary hypertension, and cancer.
Recombinant GUCY1B3 protein is engineered using expression systems (e.g., bacterial, insect, or mammalian cells) to produce purified, functional subunits for research and therapeutic development. Its production enables detailed structural and functional studies, such as mapping ligand-binding domains (e.g., for NO or sGC stimulators/activators) and investigating post-translational modifications that modulate enzyme activity. Recombinant GUCY1B3 is particularly valuable in drug discovery, aiding the development of sGC-targeted therapies for conditions like heart failure and chronic kidney disease. For example, sGC stimulators (e.g., riociguat) leverage GUCY1B3's role to enhance cGMP synthesis under oxidative stress.
Studies using recombinant proteins have also clarified mutations or polymorphisms in GUCY1B3 associated with disease susceptibility. Despite challenges in maintaining sGC heterodimer stability during recombinant production, advances in co-expression systems and purification techniques have improved protein yield and functionality. Ongoing research focuses on optimizing GUCY1B3-containing complexes for structural biology (e.g., cryo-EM) and high-throughput screening, aiming to refine precision therapeutics targeting the NO-sGC-cGMP axis.
×
